A-834735 is a drug developed by Abbott Laboratories, acts as a potent cannabinoid receptor full agonist at both the CB1 and CB2 receptors.

A-412,997 or A-412997 is a highly selective agonist for the dopamine D4 receptor. In animal tests, it improved cognitive performance to a similar extent as methylphenidate, but without producing place preference or other signs of abuse liability. When dosed systemically, A-412997 crossed the blood brain barrier rapidly. It was suggested, that selective activation of the D4 receptor, A-412997, might represent a target for the treatment of attention deficit hyperactivity disorder without the potential drug abuse liability associated with current psychostimulant therapies.